We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Point-Of-Care Tool Diagnoses Genetic Mutations within Hours

By LabMedica International staff writers
Posted on 07 Feb 2024
Print article
Image: The point-of-care kit is designed to diagnose genetic mutations (Photo courtesy of University of Calgary)
Image: The point-of-care kit is designed to diagnose genetic mutations (Photo courtesy of University of Calgary)

Blood disorders like sickle cell anemia arise from genetic mutations. Typically, newborns are screened for sickle cell disease at birth, with any irregularities reported within 96 hours. However, a follow-up blood test is necessary to confirm the diagnosis, and obtaining these results can take between two to four weeks. Often, seeking genetic analysis through specialized private laboratories can be both time-consuming and expensive. Now, a new tool can detect the presence of genetic mutations within hours instead of weeks.

Researchers at the University of Calgary (Alberta, Canada) have created a system named One-pot DTECT. This innovation is designed for simplicity and ease of use, enabling any laboratory in the world to quickly set up its own kit for same-day genetic mutation analysis at a minimal cost per sample. One-pot DTECT comprises multiple enzymes and distinct DNA fragments that work together to identify and detect genetic signatures. The compact kit includes a small metal box containing 16 vials filled with DNA fragments and an additional two vials of enzymes. This versatile kit is capable of diagnosing a broad spectrum of genetic mutations associated with various disorders, including sickle cell anemia and cystic fibrosis.

Beyond diagnosing patients, the kit is useful for routine laboratory experiments and identifying genetic mutations. The test’s accuracy has been validated, enabling direct analysis from the original blood spot with results available within hours. Discussions are underway with several companies for commercial distribution of the kits. However, the technology is simple and cost-effective, allowing laboratories to easily produce their own kits. The process simply requires specific DNA fragments for sequencing and the necessary enzymes, which are readily available from suppliers.

Related Links:
University of Calgary

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Automated Biochemistry Analyzer
AutoChem B861
New
Rheumatoid Arthritis Test
Finecare RF Rapid Quantitative Test

Print article

Channels

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.